Class summary at a glance.

Every drug in the Nonergot Dopamine Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $226.1Mcombined across class
Total Rx claims: 5.3M1.3M unique beneficiaries
Generic mfrs (active): 29across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Rotigotine

Brand: Neupro · 114K Part D claims (CY24) · 26K beneficiaries · First FDA approval: 2012-04-02

Brand-only (no generics) 18 plans require PA

Low NADAC$28.21

→

Avg plan cost$28.27

Part D spend $128.5M 1× spread, current vs floor

Class share

57%

of class CY24 spend

View profile →

Ropinirole

5.2M Part D claims (CY24) · 1.3M beneficiaries · First FDA approval: 2010-02-25

13 generic mfrs 0 plans require PA

Low NADAC$0.043

→

Avg plan cost$0.403

Part D spend $97.6M 9× spread, current vs floor

Class share

43%

of class CY24 spend

View profile →

Pramipexole Dihydrochloride

— Part D claims (CY24) · First FDA approval: 2010-10-08

16 generic mfrs 0 plans require PA

Low NADAC$0.041

→

Avg plan cost$0.929

Part D spend — 23× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.